Birthmarks are common and are seen in approximately 8% of all newborns.^[@B1]^ Though they are usually of little significance from a clinical perspective, they often are of concern to families. Fortunately, a relatively small number of these are of medical significance. Clinicians describe hemangiomas according to their growth characteristics, location, and any associated complications, such as ulceration.^[@B2]^ Discrete hemangiomas are described as focal and are distinguished from a broader or widespread growth pattern called segmental. Segmental hemangiomas, when occurring over particular areas of the body, such as the face, often can be associated with internal structural brain, vascular, cardiac, and/or eye abnormalities.^[@B3]^ The association known as PHACE syndrome is now well characterized to describe the findings of posterior fossa malformation, (segmental) hemangioma, arterial, cardiac, and eye anomalies.^[@B4],[@B5]^ With any hemangioma, management options include observation for the expected ultimate resolution, medical treatments, laser treatment, or surgical removal. Treatment of wound-related complications is also important for some such cases.

This report will focus on medical therapies for hemangiomas. Historically, corticosteroids have been used after an early observation of their effect on the proliferative phase of such lesions.^[@B6]^ A majority of hemangiomas have been seen to slow in their growth phase or stop altogether with the use of corticosteroids. Due to often high-dose and long-term use, however, growth concerns and infectious complications associated with corticosteroids have complicated their use.^[@B7]^ In 2008, a report in *The New England Journal of Medicine* described another serendipitous observation of the effect of the nonselective beta-blocker, propranolol, on hemangiomas.^[@B8]^ Since that time, multiple reports have confirmed its often remarkable effects on the growth and evolution of these common birth-marks.^[@B9],[@B10]^ Concerns regarding potential side effects and the most appropriate means of administration continue to guide ongoing clinical experience with this very exciting new treatment modality.

HISTORY
=======

A 1-month-old girl was first seen for evaluation of a facial birthmark. Her history was significant for a fetal magnetic resonance imaging study at 24 weeks\' gestation that showed absent corpus callosum after hydrocephalus was noted by ultrasound performed at 20 weeks. She was delivered by Cesarean section at 39 weeks.

An erythematous plaque was seen on the right face, upper and lower lips, and back of her head. She was felt to have a large segmental facial hemangioma, and due to the nature and location of the hemangioma, concern for PHACE syndrome was discussed with the family. Further imaging of the head and neck, as well as the heart, was ordered, and options for management of the hemangioma were discussed. An ophthalmologic examination was also conducted. Based upon imaging and eye-examination findings, PHACE syndrome was diagnosed. Laser and corticosteroids were reviewed and wound care for a small area of ulceration of the upper lip was discussed.

TREATMENT
=========

Corticosteroids were begun at the time of the initial visit at a dose of 2 mg/kg/day. Enrollment in the PHACE syndrome registry was also suggested. Patients with a diagnosis of PHACE syndrome may have any or all of the conditions associated with it (eg, large segmental/patchy facial hemangiomas, eye, brain, head/neck vessel abnormalities, heart abnormalities). Diagnostic criteria are now well described.^[@B5]^

The hemangioma stabilized over the next month. When the dose of the medication was decreased, the lesion\'s growth resumed, requiring an increase in the dose of the medication. After several months of therapy, the hemangioma again stabilized. After approximately 4 months of therapy, the report in *The New England Journal of Medicine* about propranolol use for infantile hemangiomas was discussed with the family.^[@B8]^ The patient was begun on a low dose of the medication with a slow advance of the dose concurrent with a decrease in the dose of the corticosteroid 1 month after publication of that report.

When the patient was seen in the office 1 week later, dramatic response of the hemangioma was noted. A cautious decrease of the corticosteroid was continued over the next several months, and the propranolol was continued with periodic adjustments of the dose consistent with her growth. Approximately 10 months after starting the propranolol, a tapering schedule of the medication was begun (when the patient was 15 months old). She was off of the medication approximately 1 month later.

When the patient was seen in the office 6 to 7 months later, some further ulceration of the hemangioma and discomfort were noted. Wound care and timolol solution were started.^[@B11],[@B12]^ The topical care was continued for several months with very good results ([Figure](#FU1){ref-type="fig"}).
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During the management of the hemangioma, the patient was also seen by neurology, ophthalmology, and developmental specialists.

DISCUSSION
==========

Several issues must be emphasized regarding this case. First of all, when clinicians evaluate patients with vascular birthmarks, arriving at the correct diagnosis is key to considering appropriate treatments. While most of such lesions can be easily classified, this is not always the case.^[@B13]^ Secondly, when infantile hemangiomas are diagnosed, physicians should be aware of the implications of segmental (vs focal) lesions. As noted above, criteria for consideration of PHACE syndrome must be kept in mind and the diagnosis pursued. Approximately 30% of patients with large facial segmental lesions are noted to have PHACE syndrome.^[@B14]^ In this setting, often significant head and/or neck arterial anomalies can occur, which might cause concern about the use of medications such as propranolol. While there is increasing experience with this agent for the management of large hemangiomas, a variety of methods of evaluation prior to its use exist. Similarly, some physicians begin treatment with propranolol on an outpatient basis and others (usually for selected patients) use it in the inpatient setting. At this time, the use of propranolol for this indication must be considered on an individual basis with respect to clinical need and available resources and expertise for follow-up.

Finally, this patient also received topical timolol, which is a topical beta blocker indicated for ophthalmo-logic use. Reports have cited its utility for some cases of hemangioma.^[@B11],[@B12]^ Again, matching its use to individual lesions has not been clearly defined. Issues relative to its potential absorption at certain skin sites and for particular lesions, such as ulcerated hemangiomas, also need to be clarified. In this instance, there have been no complications with its use, and some utility for ongoing management of this hemangioma has been noted by the child\'s parents and this physician.

CONCLUSION
==========

This brief report reviews the successful use of propranolol for a complicated segmental hemangioma in the setting of PHACE syndrome. Careful monitoring of blood pressure and serum glucose appears to be appropriate for ongoing use of this medication. Pretreatment evaluation is of importance for all patients being considered for such treatment and should be individualized based upon each child.
